EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

hERG1 channels and potential therapeutics for long QT syndrome

Elizabeth H Schneider, Kelly A Aromolaran, Michael C Sanguinetti, Ademuyiwa S Aromolaran

The Journal of Physiology · 01.07.2026

DOI: 10.1113/jp291452 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift The Journal of Physiology, online erschienen am 01.07.2026. Verfasst von Elizabeth H Schneider und 3 weiteren Autor:innen. Beteiligte Einrichtung: Nora Eccles Harrison Cardiovascular Research and Training Institute (CVRTI), University of Utah School of Medicine, Salt Lake City, Utah, USA. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 105 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, Nora Eccles Harrison Treadwell Foundation, National Heart, Lung, and Blood Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The human ether‐à‐go‐go‐related gene type 1 (hERG1) channel is a voltage‐gated potassium channel encoded by the KCNH2 gene. hERG1 channels are essential to the repolarization of cardiac action potentials, and reduced function of the potassium current conducted by hERG1 channels ( I Kr ) is pathogenic, leading to type 2 long QT syndrome (LQT2). LQT2 results from congenital mutation(s) of KCNH2 and affects approximately 1 in 6000 people. A mutation‐induced decrease in I Kr can be caused by altered channel gating but is most often caused by misfolding and early degradation of hERG1 protein, resulting in reduced trafficking of channels to the plasma membrane. Prolongation of the QT interval can also be drug induced, and many drugs fail preclinical safety assessments due to their inhibition of hERG1 channels. In this review we assess the molecular and structural bases of hERG1 channel function. Furthermore we examine the pharmacology of hERG1 inhibitors and hERG1 channel trafficking mediators, the pathogenesis of LQT2 that can be triggered through these mechanisms and translational and clinical perspectives that may be useful in the prevention and treatment of LQT2. By understanding the molecular mechanisms that lead to the pathophysiological development of LQT2 new therapeutics can be developed to treat this disorder. image

Schlagwörter

Stichwörter der Autor:innen

KV11.1arrhythmiaion channel gatingion channel traffickinglong QT syndrome

Autor:innen und Institutionen

  • Nora Eccles Harrison Cardiovascular Research and Training Institute (CVRTI), University of Utah School of Medicine, Salt Lake City, Utah, USA.
  • Department of Internal Medicine, Division of Cardiovascular Medicine, University of Utah, Salt Lake City, Utah, USA.
  • Department of Surgery, Division of Cardiothoracic Surgery, Biochemistry, Nutrition & Integrative Physiology, Biomedical Engineering & Molecular Medicine Program, University of Utah School of Medicine, Salt Lake City, Ut…

Förderung

  • NHLBI NIH HHS
  • Nora Eccles Harrison Treadwell Foundation
  • National Heart, Lung, and Blood Institute

Zitieren

APA

Schneider, E. H., Aromolaran, K. A., Sanguinetti, M. C., & Aromolaran, A. S. (2026). hERG1 channels and potential therapeutics for long QT syndrome. The Journal of Physiology. https://doi.org/10.1113/jp291452

Vancouver

Schneider EH, Aromolaran KA, Sanguinetti MC, Aromolaran AS. hERG1 channels and potential therapeutics for long QT syndrome. The Journal of Physiology. 2026. doi:10.1113/jp291452

BibTeX
@article{Schneider2026,
  author = {Schneider, Elizabeth H and Aromolaran, Kelly A and Sanguinetti, Michael C and Aromolaran, Ademuyiwa S},
  title = {hERG1 channels and potential therapeutics for long QT syndrome},
  journal = {The Journal of Physiology},
  year = {2026},
  doi = {10.1113/jp291452}
}
Kostenlos starten →